1887
Research Open Access
Like 0

Abstract

BACKGROUND

Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations.

AIM

We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants.

METHODS

We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points.

RESULTS

Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM.

DISCUSSION

Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.14.2500322
2026-04-09
2026-05-10
/content/10.2807/1560-7917.ES.2026.31.14.2500322
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/14/eurosurv-31-14-2.html?itemId=/content/10.2807/1560-7917.ES.2026.31.14.2500322&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Global hepatitis report 2024: Action for access in low- and middle-income countries. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240091672
  2. Bivegete S, McNaughton AL, Trickey A, Thornton Z, Scanlan B, Lim AG, et al. Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review. Euro Surveill. 2023;28(30):2200738.  https://doi.org/10.2807/1560-7917.ES.2023.28.30.2200738  PMID: 37498533 
  3. Razavi-Shearer D, Blach S, Gamkrelidze I, Estes C, Mooneyhan E, Razavi-Shearer K, et al. The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road. J Hepatol. 2022;77:S43.  https://doi.org/10.1016/S0168-8278(22)00496-2 
  4. World Health Organization (WHO). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240090903
  5. Duffell EF, van de Laar MJ. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009. Euro Surveill. 2015;20(13):17-24.  https://doi.org/10.2807/1560-7917.ES2015.20.13.21080  PMID: 25860392 
  6. European Centre for Disease Prevention and Control (ECDC). Hepatitis B. - Annual epidemiological report 2023. Stockholm: ECDC; 2025. Available from: https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-annual-epidemiological-report-2023
  7. Sperle I, Steffen G, Leendertz SA, Sarma N, Beermann S, Thamm R, et al. Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. Front public Heal. 2020;8:424.
  8. Walker N, Stover J, Stanecki K, Zaniewski AE, Grassly NC, Garcia-Calleja JM, et al. The workbook approach to making estimates and projecting future scenarios of HIV/AIDS in countries with low level and concentrated epidemics. Sex Transm Infect. 2004;80(Suppl 1) Suppl 1;i10-3.  PMID: 15249693 
  9. Koopsen J, van Steenbergen JE, Richardus JH, Prins M, Op de Coul ELM, Croes EA, et al. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population. Epidemiol Infect. 2019;147:e147.  https://doi.org/10.1017/S0950268819000359  PMID: 30869044 
  10. Kremer-Flach K, Zimmermann R, An der Heiden M, Dudareva S.Estimated number of people infected with hepatitis B and C virus in Germany in 2013: a baseline prevalence estimate using the workbook method. Front Public Health. 2025;13:1471256. https://doi.org/10.1017/S0950268819000359  PMID: 30869044 
  11. Razavi-Shearer D, Gamkrelidze I, Pan C, Jia J, Berg T, Gray R, et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879-907.  https://doi.org/10.1016/S2468-1253(23)00197-8  PMID: 37517414 
  12. Eurostat. Population on 1 January by age group, sex and country of birth (migr_pop3ctb). Luxembourg: Eurostat; 2024. Available from: https://ec.europa.eu/eurostat/databrowser/view/migr_pop3ctb/default/table?lang=en
  13. Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, et al. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2023;36:100792.  https://doi.org/10.1016/j.lanepe.2023.100792  PMID: 38188273 
  14. European Union Drugs Agency (EUDA). Viral hepatitis elimination barometer among people who inject drugs in Europe. Lisbon: EUDA. [Accessed: 14 Apr 2024]. Available from: https://www.euda.europa.eu/publications/data-factsheet/viral-hepatitis-elimination-barometer-among-people-who-inject-drugs-in-europe_en
  15. Marcus U, Hickson F, Weatherburn P, Schmidt AJ, EMIS Network. Estimating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses among MSM in 2009. BMC Public Health. 2013;13(1):919.  https://doi.org/10.1186/1471-2458-13-919  PMID: 24088198 
  16. Trickey A, Bivegete S, Duffell E, McNaughton AL, Nerlander L, Walker JG, et al. Estimating hepatitis B virus prevalence among key population groups for European Union and European Economic Area countries and the United Kingdom: a modelling study. BMC Infect Dis. 2023;23(1):457.  https://doi.org/10.1186/s12879-023-08433-3  PMID: 37430220 
  17. Council of the European Union. Refugees from Ukraine in the EU. Brussels: Council of the European Union. [Accessed: 2 Dec 2023]. Available from: https://www.consilium.europa.eu/en/infographics/ukraine-refugees-eu/
  18. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.  https://doi.org/10.1016/S0140-6736(15)61412-X  PMID: 26231459 
  19. WHO Publication. Hepatitis B vaccines: WHO position paper--recommendations. Vaccine. 2010;28(3):589-90.  https://doi.org/10.1016/j.vaccine.2009.10.110  PMID: 19896455 
  20. Galimska J. The expanded programme on immunization calendar in Poland. Vaccine. 2000;18(Suppl 1):S41-3.  https://doi.org/10.1016/S0264-410X(99)00461-2  PMID: 10683544 
  21. Statistics Denmark. Population Statistics (FOLK1C). Copenhagen, Denmark: Statistics Denmark. [Accessed: 6 Feb 2024]. Available from: https://statbank.dk/statbank5a/SelectVarVal/Define.asp?MainTable=FOLK1C&PLanguage=1&PXSId=0&wsid=cfsearch
  22. European Centre for Disease Prevention and Control (ECDC). Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016. Available from: https://www.ecdc.europa.eu/en/publications-data/systematic-review-hepatitis-b-and-c-prevalence-eueea
  23. Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145(14):2873-85.  https://doi.org/10.1017/S0950268817001947  PMID: 28891457 
  24. European Centre for Disease Prevention and Control (ECDC). Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA. Stockholm: ECDC; 2016. Available from: https://www.ecdc.europa.eu/en/publications-data/epidemiological-assessment-hepatitis-b-and-c-among-migrants-eueea
  25. Laisaar KT, Avi R, DeHovitz J, Uusküla A. Estonia at the threshold of the fourth decade of the AIDS era in Europe. AIDS Res Hum Retroviruses. 2011;27(8):841-51.  https://doi.org/10.1089/aid.2010.0223  PMID: 21142588 
  26. Marty L, Lemsalu L, Costagliola D, Vals K, Kaupe R, Linina I. The HIV Epidemic in Two Baltic States: A Tale of Two Stories? Presented at HepHIV 2019 Conference. Bucharest, Romania; 2019. Poster PS1/02. Available from: https://eurotest.org/media/ngeel30o/ps1_02.pdf
  27. European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2023–2022 data. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance-europe-2023-2022-data
  28. United Nations. Global Compact for Safe, Orderly and Regular Migration. Resolution A/RES/73/195. New York: United Nations; 2019. Available from: https://digitallibrary.un.org/record/1660537?v=pdf
  29. European Centre for Disease Prevention and Control (ECDC). Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. Stockholm: ECDC; 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-screening-and-vaccination-infectious-diseases-newly
  30. Razavi-Shearer DM, Kondili LA, Hall S, Buti M, Gamkrelidze I, Naveira MCM, et al. Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study. Lancet Reg Health Eur. 2025;58:101452.  https://doi.org/10.1016/j.lanepe.2025.101452  PMID: 40980817 
  31. European Centre for Disease Prevention and Control (ECDC). Prevention of hepatitis B and C in the EU/EEA. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/prevention-hepatitis-b-and-c-eueea-2024
  32. European Centre for Disease Prevention and Control (ECDC). Monitoring of the responses to the hepatitis B and C epidemics in EU/EEA countries, 2023. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/monitoring-responses-hepatitis-b-and-c-epidemics-eueea-countries-2023
  33. European Centre for Disease Prevention and Control (ECDC). Testing of HIV, hepatitis B and hepatitis C in the European Union/European Economic Area (EU/EEA). Stockholm: ECDC; 2025. Available from: https://www.ecdc.europa.eu/en/publications-data/testing-hiv-hepatitis-b-and-hepatitis-c-european-union-european-economic-area
  34. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796-829.  https://doi.org/10.1016/S2468-1253(22)00124-8  PMID: 35738290 
  35. Vriend HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ, Op De Coul ELM. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect. 2013;141(6):1310-7.  https://doi.org/10.1017/S0950268812001884  PMID: 22963908 
/content/10.2807/1560-7917.ES.2026.31.14.2500322
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error